The definition and delineation of thymic tumours is by no means always a simple matter. The older literature is extremely unreliable, because it includes almost every tumour of the anterior mediastinum, even such obvious ones to exclude as metastatic growths and carcinomas of the bronchus (Seybold et al. 1950 , Keynes 1955 , Iverson 1956 , Ringertz & Lidholm 1956 , Osserman 1958 , Ericsson & Hook 1960 , Lattes 1962 . I believe that one should adhere to Iverson's three criteria: (1) That the various histological pictures seen are all a composite of one tumour. (2) That tumours such as malignant lymphomas, which may occasionally originate in the thymus, should not be considered as specific thymic tumours. (3) That tumours of doubtful origin, whose only claim to be thymic is their anterior mediastinal position, are best excluded as liable only to confuse.
Another point in diagnosis which is pertinent to thymic tumours was noted by Le Roux (1961) who wrote: 'A histological report is an expression of an opinion that must be interpreted in conjunction with clinical, radiographic and operative information, and such an opinion is in no sense oracular or beyond dispute'. With regard to histology, one feature of clinical as well as pathological importance which should perhaps be reiterated is that microscopically it is impossible to distinguish between benign and malignant thymic tumours (Murray & McDonald 1945 , Ringertz 1951 , Brunner & Wehrlin 1956 , Castleman 1960 , Ericsson & Hook 1960 , Lattes 1962 , Legg & Brady 1965 , Hale & Scowen 1967 . There is no doubt that lack of appreciation of this fact has led to many incorrect statements about the malignancy of individual thymomas.
The subject of this paper concerns the thymus in clinical perspective, and the most obvious attribute of thymic tumours in this respect is that they are rare. Their interest arises, in fact, largely from their association with other diseases (Table  1) . With the exception of Cushing's syndrome, all these diseases have clear autoimmune features. The figures showing the incidence of thymic tumours in some of the diseases mentioned and vice versa are only approximate. My own experience is chiefly with thymic tumours associated with myasthenia gravis, and the figure of 33-50% is my estimate based on an extensive search of the literature, including papers reporting a total of over 500 thymic tumours. I should mention that six reviews published between 1932 and 1961 variously give the incidence as from 1 % to 100%. Ringertz (1951) , Keynes (1954) , Eaton & Clagett (1955) , Osserman (1958) , Robbins (1960) and Grob (1961) , although other estimates have been made. This agreement is, perhaps, somewhat surprising. For one thing, there is no doubt that the incidence of thymic tumours in a group of patients with myasthenia gravis varies with the severity of the myasthenia in the group. For example, while Ferguson (1962 Ferguson ( , 1963 The incidence also varies with age. Fig 1 shows the age at onset of symptoms of 164 patients with myasthenia gravis admitted to St Bartholomew's Hospital in a fifteen-year period (May 1945 to April 1960) and compares those with, and those without, thymic tumours. The proportion of thymic tumours (32 %.) is high because of a special interest in thymic surgery and radiotherapy. Despite this, no case of tumour was seen in a myasthenic patient whose illness started under the age of 20 years, and very few under the age of 30 years. In patients over 40 years at the time of onset, if the mild forms of myasthenia are excluded, it is probable that the true incidence of tumour in all patients with myasthenia gravis is in the region of 50 %.
Considering next the nature of the relationship between myasthenia gravis and thymic tumours, and basing my opinion on suchfactors as theresults of searches for an active extract of the tumours, the time relationships between onset of the two conditions and the results of treatment of the tumours, I do not believe that the relationship is a direct causal one either way. Space does not permit a detailed analysis of these factors, which has been published elsewhere (Hale & Scowen 1967 ). To illustrate one point, however, Fig 2 shows the survival of 12 women whose tumours were treated by radiotherapy alone, compared with that of 15 similar patients whose tumours were excised, 10 of whom had radiotherapy before operation and 5 after operation.
It is now almost certain that the relationship between thymic tumours and myasthenia gravis is via a third disorder, and that this disorder is autoimmune activity. The functions of the thymus in immunity and the autoimmune association, though by no means necessarily the etiology, of myasthenia gravis, make such a relationship entirely feasible, even if we do not at present know the precise details of it.
What, then, is the clinical significance of the finding of a thymic tumour in a patient with myasthenia gravis ? First, it is that the myasthenia is likely to be of the severe type. Perhaps relating this to the association of the two diseases is that there will also be a 95 % chance, as opposed to a 30 % chance in all patients with myasthenia gravis, of the patient having antibodies directed against cytoplasmic structures in thymic epithelial cells which cross-react with 'A' bands in striated muscle (New EnglandJournal ofMedicine 1966) . It should be noted, however, that the site of dis. turbed function in myasthenia gravis is not thought to be at the 'A' bands. Also, to make matters more complicated, antibodies to both thymus and muscle have been found in nonmyasthenic patients with thymic tumours (McFarlin et al. 1966) .
Returning to the severity of the disease, about 95% of patients with myasthenia gravis and a The chief features to note are its exponential nature, and the considerably better outlook for women as compared with men, 50 % surviving 9j years in the former but only 4j years in the latter. The survival times in general are perhaps better than is sometimes thought to be the case.
Secondly, patients with myasthenia gravis and a thymic tumour are at risk fiom their tumours. However, in cases where the tumour has been treated, and there are no substantial series reported in which they have not, this is nothing like so important as the myasthenia. In the 53 patients referred to above, about 1 in 4 of the men and 1 in 8 of the women had tumours which showed some manifestation of malignancy. This is nearly always local spread in continuity or spread by implantation giving pleural deposits. Metastatic or embolic spread is very iare, but the pleural deposits can themselves spread in continuity, for example through the chest wall or through the diaphragm.
When benign, the tumours played no apparent part in the patients' deaths, and when malignant they were, so far as could be estimated, only half as important as the myasthenia in causing a fatal outcome. On this basis I would say that the risk to all patients with myasthenia gravis of dying of the malignancy of a thymic tumour is about 1 in 100, and to those with a known thymic tumour about 1 in 15. As for symptoms arising from the tumours in the 53 patients, these occurred as a primary event in one patient, and eventually developed in 4 patients, all such symptoms arising from malignant spread. As might be expected from these figures, most thymic tumours associated with myasthenia gravis are discovered by investigations during the evaluation of the myasthenia, and their diagnosis often depends on the adequacy of the radiology.
Much the same appears to apply to the association of thymic tumours and the other diseases listed in Table 1 , as it does to their association with myasthenia gravis, although Cushing's syndrome is an exception. The commonest one, 'pure red cell anmmia' (Hale & Scowen 1967 , p 8, Hirst & Robertson 1967 ), has about one-tenth the incidence of myasthenia gravis in patients with thymic tumouis, the patients are older than in w.yasthenia, the presence of malignancy in the tumours is rare and the tumours play an even less direct part in the patients' illnesses. The last two features could well derive from the age difference. thymic tumours and Cushing's syndrome, myasthenia gravis and 'pure red cell anemia'. The patients with myasthenia gravis are the 53 previously mentioned, while those with Cushing's syndrome are the first 13, and those with 'pure red cell anemia' approximately the first 39, reported in the literature (for details of the sources see Hale & Scowen 1967, p 8) . The age range of the patients with myasthenia gravis and that of those with 'pure red cell anwmia' are about the same, but most of the myasthenic patients are in the middle of the range while most of those with anamia are in its upper part. Illustrating the inverse relationship between age and malignancy of thymic tumours is the incidence of malignancy in the three groups of patients, namely 46% in those with Cushing's syndrome, 20% in those with myasthenia gravis and 8% in those with 'pure red cell anmmia'. The relationship between thymic tumours and Cushing's syndrome is probably quite different from that of the other associated diseases in that the Cushing's syndrome is due, as in other cases with so-called non-endocrine tumours, to the secretion of an adrenocorticotrophin-like substance by the tumour, as in the patients recently reported by Lemon et al. (1966) and by Miura et al. (1967) . There is also a histological difference, the tumours being of a more uniform appearance, consisting almost entirely of epithelial cells and being similar microscopically to bronchial carcinomas and adenomas associated with Cushing's syndrome, and to the metastases, although not to the primary tumours, of pulmonary oat cell carcinomas so associated (Thorne 1952 , Scholz & Bahn 1959 , Cohen et al. 1960 .
Of thymic tumours unassociated with other disease (lone thymic tumours), a considerable proportion are asymptomatic and are found by mass radiography or when an X-ray examination of the chest is made for an unrelated purpose, or as an incidental post-mortem finding. In various series, asymptomatic cases have ranged from 13 % to 92%, and in all they probably amount to at least 60%. The symptoms which do occur can be divided into three groups: (1) Pain or discomfort from direct pressure. (2) Cough, dyspncea, palpitations, &c., from interferencewith the heart, lungs or pleura. (3) Obstruction of the superior vena cava.
It is impossible completely to separate lone thymic tumours from those with myasthenia gravis or other associated disease on the basis either of their histology or of their clinical behaviour (Hale & Scowen 1967, p 63) . However, unlike the case of thymic tumours associated with other diseases, the prognosis of lone thymic tumours depends very much on whether they are malignant or not, remembering that malignancy must be diagnosed clinically and not histologically. Published series suggest that about onethird of the patients die in the first year after diagnosis, and a little more than a half by the end of the second year. The remainder for the most part have benign tumours, and their outlook over the next ten years is excellent. In fact, the overall outlook is probably better than these figures indicate as malignant cases are more likely to be reported than benign ones.
Conclusions
Thymic tumours are of considerable interest to clinicians and to pathologists, both in their own right and because of their association with other conditions. I am sure they are well worth continued study but I suspect that, although this may incidentally throw further light on the associated diseases, it will not establish a primary cause for them in the thymus itself.
